Education
About Us
Working with TipRanks
Follow Us
Royalty Pharma PLC (RPRX)
NASDAQ:RPRX
RPRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$24.05 - $38.00
Previous CloseN/A
Volume726.99K
Average Volume (3M)5.07M
Market Cap
$20.44B
Enterprise Value$30.79B
Total Cash (Recent Filing)$1.49B
Total Debt (Recent Filing)$8.00B
Price to Earnings (P/E)15.3
Beta0.23
Next Earnings
Nov 05, 2025EPS Estimate
1.04Last Dividend Ex-Date
Aug 15, 2025Dividend Yield2.48%
Share Statistics
EPS (TTM)1.14
Shares Outstanding432,293,060
10 Day Avg. Volume7,366,584
30 Day Avg. Volume5,073,625
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.51
Enterprise Value/Revenue13.36
Enterprise Value/Gross Profit13.36
Enterprise Value/Ebitda15.95
Forecast
1Y Price Target
$44.00Price Target Upside25.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Product ApprovalsImdelltra was recently approved for an advanced stage of small cell lung cancer, showing potential for significant market impact.
Revenue GrowthAll key metrics have outperformed and the company is on track to meet or exceed its $4.7B 2030 revenue target.
Strategic PartnershipsRPRX announced a funding agreement with ZBIO for up to $300 million for the potential US commercial launch of obexelimab in IgG4-Related Disease.
Bears Say
Investor ConcernsRPRX has identified frequently asked questions among investors that have kept some on the sidelines.
Market RisksManagement sees pancreatic cancer as a significant value driver due to the lack of treatment options, highlighting the potential impact of the daraxonrasib asset.
Royalty Pharma News
RPRX FAQ
What was Royalty Pharma PLC’s price range in the past 12 months?
Royalty Pharma PLC lowest stock price was $24.05 and its highest was $38.00 in the past 12 months.
What is Royalty Pharma PLC’s market cap?
Royalty Pharma PLC’s market cap is $20.44B.
When is Royalty Pharma PLC’s upcoming earnings report date?
Royalty Pharma PLC’s upcoming earnings report date is Nov 05, 2025 which is in 37 days.
How were Royalty Pharma PLC’s earnings last quarter?
Royalty Pharma PLC released its earnings results on Aug 06, 2025. The company reported $1.141 earnings per share for the quarter, beating the consensus estimate of $1.032 by $0.109.
Is Royalty Pharma PLC overvalued?
According to Wall Street analysts Royalty Pharma PLC’s price is currently Undervalued.
Does Royalty Pharma PLC pay dividends?
Royalty Pharma PLC pays a Quarterly dividend of $0.22 which represents an annual dividend yield of 2.48%. See more information on Royalty Pharma PLC dividends here
What is Royalty Pharma PLC’s EPS estimate?
Royalty Pharma PLC’s EPS estimate is 1.04.
How many shares outstanding does Royalty Pharma PLC have?
Royalty Pharma PLC has 432,293,060 shares outstanding.
What happened to Royalty Pharma PLC’s price movement after its last earnings report?
Royalty Pharma PLC reported an EPS of $1.141 in its last earnings report, beating expectations of $1.032. Following the earnings report the stock price went down -2.07%.
Which hedge fund is a major shareholder of Royalty Pharma PLC?
Currently, no hedge funds are holding shares in RPRX
Royalty Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$44.00 (25.57% Upside)
$44.00 (25.57% Upside)
Blogger Sentiment
Bullish
RPRX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 10.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.6%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.77%
12-Months-Change
Fundamentals
Return on Equity
15.92%
Trailing 12-Months
Asset Growth
3.77%
Trailing 12-Months
Company Description
Royalty Pharma PLC
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
RPRX Company Deck
RPRX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlights strong financial performance and shareholder returns, a significant collaboration with Revolution Medicines, and positive clinical outcomes, alongside increased guidance and cost efficiencies. However, it also mentions a notable dispute with Vertex and one-time expense impacts.View all RPRX earnings summariesRPRX Revenue Breakdown
93.34% Income from financial royalty assets
6.62% Other royalty income
0.04% Revenue from intangible royalty assets
RPRX Stock 12 Month Forecast
Average Price Target
$44.00
▲(25.57% Upside)
Technical Analysis
Ownership Overview
1.85% Insiders
25.09% Mutual Funds
23.76% Other Institutional Investors
32.91% Public Companies and
Individual Investors